Novartis CEO dismisses talk of AstraZeneca purchase

Share this article:
Novartis CEO Daniel Vasella yesterday dismissed talk of the Swiss drugmaker’s interest in purchasing AstraZeneca, Reuters reported. “You shouldn’t expect any major transaction on our side,” Vasella told analysts in a post-results Web cast. “You can forget when you hear about AstraZeneca or other companies.” Novartis, along with GlaxoSmithKline, has been repeatedly mentioned by analysts as a potential bidder for AstraZeneca.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.